Abstract
We provide a novel way to correct the effective reproduction number for the time-varying amount of tests, using the acceleration index (Baunez et al., 2021) as a simple measure of viral spread dynamics. Not correcting results in the reproduction number being a biased estimate of viral acceleration and we provide a formal decomposition of the resulting bias, involving the useful notions of test and infectivity intensities. When applied to French data for the COVID-19 pandemic (May 13, 2020 - October 26, 2022), our decomposition shows that the reproduction number, when considered alone, characteristically underestimates the resurgence of the pandemic, compared to the acceleration index which accounts for the time-varying volume of tests. Because the acceleration index aggregates all relevant information and captures in real time the sizable time variation featured by viral circulation, it is a more parsimonious indicator to track the dynamics of an infectious disease outbreak in real time, compared to the equivalent alternative which would combine the reproduction number with the test and infectivity intensities.
JEL Classification Numbers I18; H12
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
* This draft supersedes an earlier version titled “The Acceleration Index as a Test-Controlled Reproduction Number: Application to COVID-19 in France”. The authors thank conference and seminar participants at the AC Transmission-Inserm, IHU Méditerranée Infection, Pan-African Scientific Research Council, Bordeaux School of Economics, Toulouse School of Economics, for useful comments, as well as the Editor and both referees for suggestions that prompted us to improve the draft.
Email:christelle.baunez{at}univ-amu.fr
Email:mickael.degoulet{at}univ-amu.fr
Email:stephane.luchini{at}univ-amu.fr
Email:matteo.pintus{at}agroparistech.fr
Email:patrick.pintus{at}univ-amu.fr
Email:miriam.teschl{at}ehess.fr
Analysis in Section 3 has been extended to include years 2021 and 2022. New appendix on data description and computational processing.
Data Availability
Data used publicly available.
